| Completed | A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensi NCT07086651 | Pfizer | — |
| Recruiting | Novel Therapy Target in Metastatic Prostate Cancer NCT05577689 | Fudan University | — |
| Completed | Effects of Music and Conversation in Prostate Biopsy NCT07006779 | Bozok University | N/A |
| Recruiting | A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive a NCT04633252 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castra NCT03531827 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors NCT03685591 | Pfizer | Phase 1 |
| Completed | A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment NCT03572387 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Completed | Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy NCT03388619 | National Cancer Institute (NCI) | Phase 1 |
| Enrolling By Invitation | Fusion Guided Focal Laser Ablation of Prostate Cancer NCT02759744 | National Institutes of Health Clinical Center (CC) | N/A |
| Terminated | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physicia NCT02900248 | CureOne | — |
| Enrolling By Invitation | 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer NCT03181867 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Evaluating the Role of Both PSMA and 64Cu-PET/CT Total Body in Patients With Locally Relapsed Prostate Cancer NCT04703543 | Regina Elena Cancer Institute | N/A |
| Active Not Recruiting | 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer NCT03173924 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases NCT02582749 | Ajjai Alva, MD | Phase 2 |
| Completed | Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer NCT02649855 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer NCT02334579 | Swedish Medical Center | N/A |
| Completed | Prostate Cancer Stereotactic Radiotherapy NCT02319239 | Tampere University Hospital | N/A |
| Withdrawn | Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino NCT01692483 | Janssen Pharmaceutica | — |
| Completed | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alo NCT01715285 | Janssen Research & Development, LLC | Phase 3 |
| Completed | A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cance NCT01695135 | Janssen Research & Development, LLC | Phase 3 |
| Completed | Sipuleucel-T Manufacturing Demonstration Study NCT01477749 | Dendreon | Phase 2 |
| Completed | A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modif NCT01424930 | Janssen-Ortho Inc., Canada | Phase 2 |
| Unknown | Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer NCT01581749 | Albert DeNittis | Phase 4 |
| Completed | A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic C NCT01400555 | Cougar Biotechnology, Inc. | Phase 1 |
| Completed | A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patie NCT01284920 | Astellas Pharma Inc | Phase 1 / Phase 2 |
| Completed | A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Canc NCT01228760 | Astellas Pharma Inc | Phase 1 |
| Terminated | Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Simulator NCT00999960 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in NCT01017939 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Abl NCT00970203 | Roswell Park Cancer Institute | Phase 2 |
| Completed | A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the NCT00972309 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastat NCT00910754 | Janssen Research & Development, LLC | Phase 1 |
| Completed | CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution NCT00643994 | Accuray Incorporated | N/A |
| Completed | CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry NCT00643617 | Accuray Incorporated | N/A |
| Completed | An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cance NCT00544440 | Janssen Research & Development, LLC | Phase 2 |
| Completed | A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prosta NCT00600535 | Cougar Biotechnology, Inc. | Phase 1 |
| Completed | An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed C NCT01664728 | Janssen Research & Development, LLC | Phase 1 |
| Completed | An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed A NCT00474383 | Cougar Biotechnology, Inc. | Phase 2 |
| Completed | Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer NCT00298155 | University of Washington | Phase 2 |
| Completed | Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer NCT00473746 | Janssen Research & Development, LLC | Phase 1 / Phase 2 |
| Completed | Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer NCT00167648 | University of Washington | Phase 2 |
| Enrolling By Invitation | Use of Tracking Devices to Locate Abnormalities During Invasive Procedures NCT00102544 | National Institutes of Health Clinical Center (CC) | N/A |
| Completed | PS-341 Followed by Removal of Prostate for Those With Prostate Cancer NCT00425503 | Baylor College of Medicine | Phase 2 |
| No Longer Available | A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic NCT01834209 | Janssen Research & Development, LLC | — |
| Approved For Marketing | Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer NCT01217697 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | — |